

## **Title: European Training & Research in Peritoneal Dialysis – presentation on EU founded program**

Katarzyna Białas<sup>1,2</sup>, Klaus Kratochwill<sup>1,2</sup>

1. Zytotec, Vienna, Austria
2. Medical University of Vienna, Vienna, Austria

Peritoneal dialysis (PD) is, besides hemodialysis, a standard form of life-sustaining renal replacement therapy for patients with end stage renal disease. Although both dialysis forms have similar mortality rates, PD is characterized by a more advantageous life-expectancy rate in early phase of treatment, better quality of life including home-based treatment opportunities as well as higher cost-efficiency. Nevertheless, only around 10 % of European dialysis population is treated with this modality. As PD research faced a deficit in workforce and scientific expertise, probably through competition with other specializations, the absence of a coherent training program and limited trans-European collaboration, the EuTRiPD project was initiated.

EuTRiPD (European Training & Research in PD) is a European Union funded project, started 2011 as Marie Curie Initial Training Network and ended 2015, for training 12 early stage researchers across leading European PD research centers. Eight research institutes (VU Medical Center Amsterdam, Medical University of Vienna, Cardiff University, Poznan University of Medical Sciences, Charite University of Medicine Berlin, Heidelberg University, Spanish National Research Council Madrid and University of Strasbourg), one SME (Zytotec) and one large private company (Baxter) together with associated partners provided an inter-disciplinary and intersectoral long lasting training programme in PD research and as consortium created a platform for increasing public awareness. Moreover, the network built within EuTRiPD enable fulfilling of the long term scientific objectives by conducting translational research of identified diagnostic and therapeutic tools to better predict the outcomes in PD patients and to overcome the limitations of PD.

One of the novel therapeutic interventions developed by Zytotec - innovative peritoneal dialysis fluid ICOPROTEC supplemented with cytoprotective agent - was the subject of the project within EuTRiPD and was investigated in *in-vitro* phase to provide the basis for further *in-vivo* and clinical study to offer an improved PD therapy.